Treating oestrogen receptor-positive breast cancer tumours with a combination of fidarestat (an inhibitor of aldose reductase enzyme) and letrozole (an aromatase inhibitor) could delay or stop tumour resistance to endocrine therapy. Single agents are less effective. Many tumors develop resistance, so this combination approach could prolong that window when endocrine therapy is effective. Official San Antonio Breast Cancer Symposium press conference.